MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants



Similar documents
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Anticoagulant therapy

Analytical Specifications RIVAROXABAN

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

DVT/PE Management with Rivaroxaban (Xarelto)

The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences

Traditional anticoagulants

Preventing Blood Clots After Hip or Knee Replacement Surgery or Surgery for a Broken Hip. A Review of the Research for Adults

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Comparison between New Oral Anticoagulants and Warfarin

Anticoagulation Essentials! Parenteral and Oral!

Anticoagulants in Atrial Fibrillation

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services

East Kent Prescribing Group

Rivaroxaban (Xarelto ) by

Dabigatran (Pradaxa) Guidelines

Critical Bleeding Reversal Protocol

Anticoagulation and Reversal

The Role of the Newer Anticoagulants

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center

Management for Deep Vein Thrombosis and New Agents

Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014

The new oral anticoagulants & the future of haemostasis laboratory testing. Alcohol: the good, the bad and the ugly

Drugs that alter. blood coagulation. Brush up on your knowledge of these potentially life-saving drugs. By Amy M. Karch, RN, MS

Anticoagulants. Anticoagulants Definition. When are blood clots GOOD? Where and why do blood clots occur? 6/12/2014

How To Compare The New Oral Anticoagulants

Summary Review. Newer Oral Anticoagulant Drugs

Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, Committee Approval Date: July 11, 2014 Next Review Date: July 2015

Investor News. Not intended for U.S. and UK media

Title of Guideline. Thrombosis Pharmacist)

FDA Approved Oral Anticoagulants

3/3/2015. Patrick Cobb, MD, FACP March 2015

New Oral Anticoagulants. How safe are they outside the trials?

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Cardiovascular Disease

Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

LAMC Reversal Agent Guideline for Anticoagulants Time to resolution of hemostasis (hrs) Therapeutic Options

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.

Reversing the New Anticoagulants

Program Objectives. Why Use Anticoagulants? 6/5/2014

ABOUT XARELTO CLINICAL STUDIES

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Dr Gordon Royle Haematologist, Middlemore Hospital

5/21/2012. Perioperative Use Issues. On admission: During hospitalization:

CONTEMPORARY REVERSAL OF ANTICOAGULATION

2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS

An#- Coagulant An#- Thrombo#c An#- Platelet Drugs

The Brave New (Anticoagulant) World

Pradaxa and Xarelto : Coming Soon to Your Practice!!

What You Need to KnowWhen Taking Anticoagulation Medicine

DISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose

Recommendation for the Reversal of Novel Anticoagulants in Emergent Situations

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

CLINICAL PRACTICE GUIDELINE: MOBILITY WITH A DEEP VEIN THROMBOSIS (DVT) Page 1 of 10

To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.

Anticoagulation before and after cardioversion; which and for how long

Dr Gordon Royle Haematologist, Middlemore Hospital

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT

Oral Anticoagulants: What s New?

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

How To Understand The History Of Analgesic Drugs

Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare

Antithrombotic therapy

New Oral Anticoagulant Drugs What monitoring if any is required?

MANAGING BLEEDING IN THE

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

DOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant

NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

New Oral Anticoagulants for VTE, A-fib, and ACS

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

Cardiovascular Subcommittee of PTAC Meeting held 27 February (minutes for web publishing)

Objectives. Patient Background. Transitioning a Patient To & From a New Oral Anticoagulant

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto

New anticoagulants: Monitoring or not Monitoring? Not Monitoring

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

Module 1: Orthopedic Surgery: Disease State

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

Treatment with Rivaroxaban

Rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery

Cardiology Medications New Drugs, New Guidelines

Transcription:

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about how anticoagulants work we need to review the clotting cascade. Simply: When you injure a blood vessel the first thing that happens is the vessel constricts. With the injured blood vessel constricted, the platelets present in the blood that is passing through that vessel start to stick to the collagen fibers that are part of the blood vessel wall. Eventually, a platelet plug forms, and it fills small tears in the blood vessel. Once the platelet plug is formed, a chain of events is initiated to form a clot. The reactions that occur are catalyzed by enzymes called clotting factors. There are 12 clotting factors, and the mechanism that occurs is very complex. Here are just a few highlights of what happens during the clotting process: After a platelet plug forms, the coagulation phase begins, which involves a cascade of enzyme activations that lead to the conversion of prothrombin to thrombin. Calcium is required for this reaction to occur. Thrombin itself acts as an enzyme and causes fibrinogen one of the two major plasma proteins to form long fibrin threads. Fibrin threads entwine the platelet plug forming a mesh-like framework for a clot. The framework traps red blood cells that flow toward it, forming a clot. Because red blood cells are tangled in the meshwork, clots appear to be red. As the red blood cells trapped on the outside dry out, the color turns a brownish red, and a scab forms. As you can see there are many steps in the clotting cascade. Anticoagulants are divided into 4 different groups depending on which part of the clotting cascade they effect. The four groups of anticoagulants are: 1. Coumarins 2. Direct thrombin inhibitors 3. Direct factor Xa inhibitors 4. Heparin

Coumarins Warfarin (trade name: Coumadin) is the main drug listed in this category. It works by inhibiting Vitamin K expoxide reluctase, an enzyme that recycles oxidized vitamin K. Vitamin K is an activator of coagulating factors II, VII, IX and X, so by decreasing the availability of Vitamin K synthesis of these factors are decreased. Warfarin is used to treat blood clots in cases of deep vein thrombosis or pulmonary embolism. It is also used to prevent thrombosis in patients at high risk such as atrial fibrillation, heart attack, and knee or hip surgery. Warfarin is taken orally. The dose varies and is regulated by the patient s INR level. This requires monthly blood testing. It s half life is 36 hours and its primary route of elimination is the liver. Patients must be careful with their diet making sure their Vitamin K intake remains constant. The primary adverse effect associated with warfarin is bleeding. This effect is reversible using Vitamin K and fresh frozen plasma. Direct Thrombin Inhibitors Dabigatran (trade name Pradaxa) is the most commonly found drug in this category. Thrombin inhibitors are anticoagulants that bind to and inhibit the activity of thrombin therefore prevent blood clot formation. Thrombin inhibitors inactivate free thrombin and also the thrombin that is bound to fibrin. Thrombin has many important functions in the clotting pathway, so it is a good target for anticoagulants drugs. Thrombin inhibitors are used to prevent arterial and venous thrombosis. They can be used to prevent and treat deep vein thrombosis, or used as prophylaxis in atrial fibrillation to avoid thromboembolism.

Dabigatran is taken orally. The dose is 150mg twice daily (75mg twice daily for people with renal impairment. It does not affect a patient s INR and monthly monitoring is not necessary. The half life of the drug is 12 17 hours and it primarily eliminated by the kidneys. This medicine is not affected by diet. Adverse effects may include bleeding and indigestion or stomach upset. Unlike warfarin there is no reversal agent for this medication in the case of major bleeding. Direct Factor Xa Inhibitors. Rivaroxaban (trade name Xarelto) is the most commonly found drug in this category. Factor Xa inhibitors are anticoagulants that block the activity of clotting factor Xa and prevents blood clots developing or getting worse. Factor Xa is generated by both the extrinsic and intrinsic coagulation pathways, it activates prothrombin to thrombin, which activates the final components of the coagulation pathway to form clots. Factor Xa inhibitors are generally used as prophylaxis in patients having hip and knee replacement surgery, where blood clots can form and lead to deep vein thrombosis and pulmonary embolism. It is also used for the prevention of stroke/systemic embolism in patients with non-valvular atrial fibrillation. Rivaroxaban is taken orally. The dose is 10mg once daily for the prevention of thromboembolism and 20mg once daily for the patient with atrial fibrillation. Just like Dabigatran the patient s INR is not affected so monthly lab work is not necessary. The half life is 5 13 hours and is eliminated by the kidneys and liver. This medicine is not affected by diet. Adverse effects are bleeding. There is not reversal agent for this medication in the case of major bleeding. Heparin Heparin is an injectable anticoagulant that activates antithrombin III, which inhibits thrombin and factor Xa, factors necessary in the final stages of blood clotting cascade. There are two types of heparins: high molecular weight heparins and low molecular weight heparins. High molecular weight heparins require daily blood monitoring to check the aptt. Low molecular weight heparins such as Enoxaparin (trade name Lovenox) give a better anticoagulant response and do not need daily blood monitoring.

Heparin is used to treat or prevent clots in conditions where there is a high risk of clot formation and thromboembolism, such as in atrial fibrillation, myocardial infarction, deep vein thrombosis, knee and hip surgery and so on. Dosage and half life varies depending on whether high or low molecular heparin is used. Drugs in this group unlike the other anticoagulants is given by injection. Major adverse effects are bleeding and thrombocytopnea. In the case of major bleeding the drug protamine may be used to reverse the effects.

McHenry Western Lake County EMS System OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Name: Date: Dept: 1. List the 4 groups of anticoagulants A. B. C. D. 2. The generic name for Coumadin is. 3. List 2 indications for the use of anticoagulants., 4. A major side effect of all anticoagulants is. 5. The most common Direct Thrombin inhibitor is. 6. is the drug that requires monthly lab testing to determine the patient s INR. 7. Drugs in this group are given by injection.. 8. There is no reversal agent for drugs in these two groups of anticoagulants: and 9. The most common Direct Factor Xa Inhibitor is. 10. All anticoagulants affect the same part of the clotting cascade. True False.